2 completed, 1 terminated. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow SARS Pneumonia: new trials by email Literature Review of SARS Pneumonia trials Research Report on SARS Pneumonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects Fostamatinib, Placebo - Covid19, SARS (Severe Acute Respiratory Syndrome) | Phase 3 | Completed | Rigel Pharmaceuticals | 280 | 2021-03-25 | 2023-08-18 |
| Efficacy of Vitamin D Treatment in Mortality Reduction Due to COVID-19. Vitamin D, PLACEBO - SAR, SARS Pneumonia | Phase 3 | Completed | Bioaraba Health Research Institute | 108 | 2020-11-09 | 2022-07-15 |
| Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers Tocilizumab - COVID, SARS Pneumonia | Phase 3 | Terminated | Beneficência Portuguesa de São Paulo | 129 | 2020-05-08 | 2020-08-26 |
COVID-19 (1) · Cytokine Release Syndrome (1) · Pneumonia (1) · Pneumonia, Viral (1) · Severe Acute Respiratory Syndrome (1)
Coronaviridae Infections (1) · Coronavirus Infections (1) · Infections (1) · Inflammation (1) · Lung Diseases (1) · Nidovirales Infections (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · RNA Virus Infections (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1) · Shock (1) · Systemic Inflammatory Response Syndrome (1) · Virus Diseases (1)
Vitamin D (1) · fostamatinib (1) · tocilizumab (1)
Beneficência Portuguesa de São Paulo (1) · Bioaraba Health Research Institute (1) · Rigel Pharmaceuticals (1)
Brazil (2) · Argentina (1) · Mexico (1) · Spain (1) · United States (1)